Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy

被引:24
作者
Xu, Yanjun [1 ]
Li, Hui [1 ]
Huang, Zhiyu [1 ]
Chen, Kaiyan [1 ]
Yu, Xiaoqing [1 ]
Sheng, Jiamin [1 ]
Zhang, Han-Han [2 ]
Fan, Yun [3 ]
机构
[1] Chinese Acad Sci, Dept Med Thorac Oncol, Inst Canc Res & Basic Med Sci, Univ Chinese Acad Sci,Zhejiang Canc Hosp,Canc Hos, Hangzhou, Peoples R China
[2] Burning Rock Biotech, Guangzhou, Peoples R China
[3] Wenzhou Med Univ, Wenzhou, Peoples R China
关键词
Genome; immunotherapy; lung squamous cell carcinoma (LUSC); programmed cell death ligand-1 (PD-L1); tumor mutational burden (TMB); OPEN-LABEL; CANCER; NIVOLUMAB; CHEMOTHERAPY; DOCETAXEL; BLOCKADE; MULTICENTER; PHASE-3; KEY;
D O I
10.21037/tlcr-20-1130
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Immune checkpoint inhibitors (ICIs) prolong overall survival (OS) in patients with advanced lung squamous cell carcinoma (LUSC). However, predictive and prognostic factors related to ICis in LUSC remain elusive. This study aimed to identify predictors that are related to better clinical benefit and outcomes in LUSC patients treated with immunotherapy. Methods: Capture-based targeted sequencing was performed in 64 patients with advanced LUSC who underwent immunotherapy. Tumor mutational burden (TMB) was defined as the sum of nonsynonymous single nucleotide and indel variants. Programmed cell death ligand-1 (PD-L1) expression was evaluated by immunohistochemical analysis. Clinicopathological characteristics including age, sex, performance status, smoking history, body mass index (BMI), blood fat, brain metastases, liver metastases, previous thoracic radiotherapy, and treatment lines were analyzed. Results: The most commonly mutated genes included TP53, CDKN2A, KEAP1, CRERRP, KRAS, RIM, AMER1, and APC. Copy number variations most frequently occurred in AR, SOX2, PIK3CA, EGFR, RICTOR, FGFR1, and ZNF703. The median and mean TMB was 9.35 and 10.62 mutations per megabase, respectively. Positive PD-LI expression was detected in 29.7% patients. Patients with a history of heavy smoking 40 pack-years) were more likely to have positive PD-L1 expression (35% vs. 16.7%, P=0.04) and higher TMB (11.1 vs. 9.8 mut/Mb, P=0.04). Gene alterations had no impact on PD-L1 expression or TMB level. The median progression-free survival (PFS) was 6.7 months and median OS was 13.7 months. Higher TMB was independently associated with longer PFS (P=0.01) and OS (P=0.02), and this correlation was more pronounced in patients treated with ICIs as a single agent (P=0.0001). Higher TMB was also associated with better disease control rate (DCR) (P=0.02). Compared with wild-type, patients with KRAS mutation and EGFR amplification had higher objective response rates (ORR, P=0.01). Conclusions: The predictive value of TMB is more significant in LUSC patients receiving ICI as a single agent than as a combination therapy. The combination of Eastern Cooperative Oncology Group performance status (ECOG-PS), smoking status, TMB, PIMA, and genomic variation might be helpful for personalized immunotherapy decisions in clinical practice for advanced LUSC.
引用
收藏
页码:2367 / 2379
页数:21
相关论文
共 38 条
  • [1] Deciphering Signatures of Mutational Processes Operative in Human Cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Campbell, Peter J.
    Stratton, Michael R.
    [J]. CELL REPORTS, 2013, 3 (01): : 246 - 259
  • [2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [3] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
  • [4] Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
    Cristescu, Razvan
    Mogg, Robin
    Ayers, Mark
    Albright, Andrew
    Murphy, Erin
    Yearley, Jennifer
    Sher, Xinwei
    Liu, Xiao Qiao
    Lu, Hongchao
    Nebozhyn, Michael
    Zhang, Chunsheng
    Lunceford, Jared
    Joe, Andrew
    Cheng, Jonathan
    Webber, Andrea L.
    Ibrahim, Nageatte
    Plimack, Elizabeth R.
    Ott, Patrick A.
    Seiwert, Tanguy
    Ribas, Antoni
    McClanahan, Terrill K.
    Tomassini, Joanne E.
    Loboda, Andrey
    Kaufman, David
    [J]. SCIENCE, 2018, 362 (6411) : 197 - +
  • [5] Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
    Dong, Zhong-Yi
    Zhong, Wen-Zhao
    Zhang, Xu-Chao
    Su, Jian
    Xie, Zhi
    Liu, Si-Yang
    Tu, Hai-Yan
    Chen, Hua-Jun
    Sun, Yue-Li
    Zhou, Qing
    Yang, Jin-Ji
    Yang, Xue-Ning
    Lin, Jia-Xin
    Yan, Hong-Hong
    Zhai, Hao-Ran
    Yan, Li-Xu
    Liao, Ri-Qiang
    Wu, Si-Pei
    Wu, Yi-Long
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (12) : 3012 - 3024
  • [6] Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer
    Fang, Wenfeng
    Ma, Yuxiang
    Yin, Jiani C.
    Hong, Shaodong
    Zhou, Huaqiang
    Wang, Ao
    Wang, Fufeng
    Bao, Hua
    Wu, Xue
    Yang, Yunpeng
    Huang, Yan
    Zhao, Hongyun
    Shao, Yang W.
    Zhang, Li
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (16) : 5015 - 5026
  • [7] CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
    Felip, Enriqueta
    Ardizzoni, Andrea
    Ciuleanu, Tudor
    Cobo, Manuel
    Laktionov, Konstantin
    Szilasi, Maria
    Califano, Raffaele
    Carcereny, Enric
    Griffiths, Richard
    Paz-Ares, Luis
    Duchnowska, Renata
    Alonso Garcia, Miriam
    Isla, Dolores
    Jassem, Jacek
    Appel, Wiebke
    Milanowski, Janusz
    Van Meerbeeck, Jan P.
    Wolf, Juergen
    Li, Ang
    Acevedo, Angelic
    Popat, Sanjay
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 127 : 160 - 172
  • [8] Hyperprogression as a distinct outcome after immunotherapy
    Fuentes-Antras, J.
    Provencio, M.
    Diaz-Rubio, E.
    [J]. CANCER TREATMENT REVIEWS, 2018, 70 : 16 - 21
  • [9] Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%
    Gainor, J. F.
    Rizvi, H.
    Aguilar, E. Jimenez
    Skoulidis, F.
    Yeap, B. Y.
    Naidoo, J.
    Khosrowjerdi, S.
    Mooradian, M.
    Lydon, C.
    Illei, P.
    Zhang, J.
    Peterson, R.
    Ricciuti, B.
    Nishino, M.
    Roth, J. A.
    Grishman, J.
    Anderson, D.
    Little, B. P.
    Carter, B. W.
    Arbour, K.
    Sauter, J. L.
    Mino-Kenudson, M.
    Heymach, J., V
    Digumarthy, S.
    Shaw, A. T.
    Awad, M. M.
    Hellmann, M. D.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (03) : 404 - 411
  • [10] Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme
    Grossi, Francesco
    Crino, Lucio
    Logroscino, Antonio
    Canova, Stefania
    Delmonte, Angelo
    Melotti, Barbara
    Proto, Claudia
    Gelibter, Alain
    Cappuzzo, Federico
    Turci, Daniele
    Gamucci, Teresa
    Antonelli, Paola
    Marchetti, Paolo
    Santoro, Armando
    Giusti, Sabrina
    Di Costanzo, Francesco
    Giustini, Lucio
    Del Conte, Alessandro
    Livi, Lorenzo
    Giannarelli, Diana
    de Marinis, Filippo
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 100 : 126 - 134